Ibrutinib, a TKI with high affinity for Bruton tyrosine kinase, is used in the treatment of chronic lymphocyte leukemia and has been shown to also inhibit HER4 and other TKs [6,17]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.